ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of January 14, 2026, ACRS stock price climbed to $2.74 with 349,082 million shares trading.

ACRS has a beta of 1.30, meaning it tends to be more sensitive to market movements. ACRS has a correlation of 0.14 to the broad based SPY ETF.

ACRS has a market cap of $296.69 million. This is considered a Small Cap stock.

Last quarter Aclaris Therapeutics reported $3 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.

In the last 3 years, ACRS traded as high as $18.54 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ACRS has underperformed the market in the last year with a price return of +9.6% while the SPY ETF gained +19.8%. However, in the short term, ACRS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +51.4% vs +4.5% return in SPY. But in the last 2 weeks, ACRS shares have been beat by the market, returning -9.0% compared to an SPY return of +1.2%.

ACRS support price is $2.59 and resistance is $2.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.